PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
May 18, 2023 07:00 ET
|
PepGen Inc.
- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 - - Initial data...
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments
May 11, 2023 07:00 ET
|
PepGen Inc.
– Phase 2 open-label CONNECT1-EDO51 study expected to be initiated in Canada in the first half of 2023 – – Potentially registration-directed, randomized, double-blind, placebo-controlled Phase 2...
PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference
May 04, 2023 08:00 ET
|
PepGen Inc.
BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
April 17, 2023 08:00 ET
|
PepGen Inc.
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 13, 2023 16:05 ET
|
PepGen Inc.
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
March 23, 2023 16:05 ET
|
PepGen Inc.
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference
March 22, 2023 08:00 ET
|
PepGen Inc.
- In NHP, four monthly doses of 20 mg/kg of PGN-EDO51 resulted in 34.9% exon skipped transcripts in biceps; a 14-fold increase over the 2.5% exon 51 skipped transcripts observed after a single dose – ...
PepGen to Participate in the Stifel 2023 CNS Days Conference
March 21, 2023 16:05 ET
|
PepGen Inc.
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
March 16, 2023 08:00 ET
|
PepGen Inc.
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
March 13, 2023 08:00 ET
|
PepGen Inc.
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...